Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Cure Blindness Project’s 2025 Holiday Catalog Encourages Shoppers to Give Gift of Sight
Cure Blindness Project on Nov. 18 launched its 2025 Holiday Gift Guide, which the group describes as giving shoppers a thoughtful, sustainable, and hassle-free charity gift option. The catalog offe...
Bascom Palmer Eye Institute Opens Location in Abu Dhabi
The Bascom Palmer Eye Institute, part of the University of Miami Health System, announced that it was opening its first international location in Abu Dhabi, United Arab Emirates, in November. The p...
Assistance Fund Charity Launches Aid Program for MacTel Treatment
The Assistance Fund, a charitable organization that helps patients facing high out-of-pocket medical costs, announced Nov. 3 a new financial aid program for people living with macular telangiectasi...
AAO Retina Sessions Delve into Wide-field Imaging, Diabetic Eye Disease, and More
Approximately 2,300 doctors attended the Retina Subspecialty Day at the 2025 AAO meeting, and many stayed to take part in retina sessions during the remaining days of the conference. Highlights of ...
Cartwheel to License ClearSight’s OTC Pink Eye Treatment
Cartwheel, of Boston, Massachusetts, reported Nov. 12 that it had signed a letter of intent to license ClearSight Therapeutics’ over-the-counter (OTC) pink eye treatment beginning in 2027. ClearSig...
Coave Unveils Lead Gene Therapy Program for Retinal Vascular Diseases
France’s Coave Therapeutics announced Nov. 14 the selection of its lead gene therapy program, CoTx-101, targeting retinal vascular diseases such as wet age-related macular degeneration and diabetic...
Curative Biotech Seeks Strategic Partner to Advance Metformin Eye Drops for AMD
Curative Biotechnology issued a letter to shareholders Nov. 18, outlining its plan to seek a strategic partner to advance the metformin-based eye drops it licensed from the National Eye Institute. ...
Xbrane Plans to Resubmit BLA to US FDA in March 2026 for Lucentis Biosimilar
Sweden’s Xbrane Biopharma announced Nov. 19 that it would resubmit the biologics license application (BLA) for its Lucentis (ranibizumab) biosimilar to the US FDA in March 2026. A complete response...
Precise Bio Treats First Patient With 3D Bioprinted Corneal Implant
Precise Bio announced Nov. 19 that the first patient had been treated with PB-001, the company’s 3D bioprinted corneal implant candidate, in a Phase I clinical trial. The legally blind patient was ...
Topcon Gains US 510(k) Clearance for Omnia 4-in-1 Diagnostic Device
Topcon Healthcare announced on Nov. 18 the FDA 510(k) clearance and US commercial launch of Omnia, an automated four-in-one diagnostic device that integrates objective refraction, keratometry, tono...
iOR Partners Rolls Out MD-OD Office-Based Collaboration Model
Kansas City, Missouri-based iOR Partners reported Nov. 12 that it was rolling out a newcollaboration model designed to bring together ophthalmologists (MDs) and optometrists (ODs). iOR Partners dev...
Harrow Takes Unconventional Path, Sees Soaring Revenue Growth
Harrow is making waves in ophthalmology. Product acquisitions, rapid growth, and breaking with convention are all part of CEO Mark Baum’s blueprint for building the first major new US ophthalmic co...
Past News Stories
US FDA Approves Eylea HD for RVO, Plus Monthly Dosing in All Approved Indications
Regeneron Pharmaceuticals announced Nov. 19 that the US FDA had approved Eylea HD (aflibercept 8 mg) for macular edema following retinal vein occlusion (RVO), with dosing up to every eight weeks af...
Cellution Launches AmnioPlast Allografts in US for Ocular Surface Repair
Cellution Biologics announced Nov. 19 the US launch of its AmnioPlast 1 monolayer and AmnioPlast Double dual-layer dehydrated amnion membrane allografts for ocular surface repair. The Roswell, Geor...
New Brain Stimulation Approach Improves Vision Recovery After Stroke
Researchers at Switzerland-based Ecole Polytechnique Fédérale de Lausanne reported Nov. 17 that they had successfully tested a new brain stimulation treatment to improve vision recovery in stroke p...
Two Leading Eye Banks Based in Southeastern US Announce Merger
Two US eye banks, Advancing Sight Network and Miracles In Sight, announced Nov. 6 that they would merge and begin operating as one on Jan. 1, 2026. Advancing Sight Network, of Birmingham, Alabama, ...
Moria’s New Corneal Tissue Storage Medium is First in Decades
Moria aims to enhance the landscape of corneal tissue storage as it launches the first new product in the category in 30 years. “Xtra4 is the most advanced corneal storage medium we’ve ever develop...
Medicare Updates Offer Mixed Bag for Eye Doctors, AAO Policy Experts Say
Policy experts provided ophthalmologists at the 2025 AAO meeting with guidance on proposed changes to Medicare reimbursement for 2026; those changes have since been finalized and formally announced...
Lilly Makes Foray into Ophthalmic Gene Therapies with Adverum, MeiraGTx Deals
Drugmaker Eli Lilly made two significant moves recently to enter the arena of ophthalmic gene therapies, acquiring Adverum Biotechnologies in a deal worth up to $262 million, and licensing technolo...
Amsurg Acquires ASC in South Carolina, Expanding Footprint in State
Amsurg, of Nashville, Tennessee, reported Oct. 28 that it had acquired Surgery Center of Conway, in Conway, South Carolina, its fourth center in the state. Amsurg, a leader in ASC services, said th...
Select US FDA Approvals and Clearances in October 2025
The US FDA’s ophthalmic device division granted clearance to one device using the 510(k) pathway in October 2025, according to the agency’s database. OD-OS gained clearance for its Navilas 577sl la...
PDUFA Dates for Ophthalmic Drug Candidates
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
AAVantgarde Leads Latest Ophthalmic Fundraising with $141 Million in Series B
AAVantgarde Bio led recent ophthalmic fundraising efforts with $141 million in Series B funding to advance its retinal gene therapy pipeline. Financing announced in the past four weeks totaled $488...
STAAR Solicits New Bids Under Amended Deal with Alcon, Moves Shareholder Vote to Dec. 19
STAAR Surgical reported Nov. 7 that it had amended its merger agreement with Alcon to allow STAAR to solicit new buyers for 30 days under a new “go-shop” period ending Dec. 6. STAAR also delayed to...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.